Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Lemonex's mRNA-DegradaBALL Vaccine (LEM-mR203) IND Application Approved for Phase 1 Clinical Trial

Thursday, August 10, 2023

Lemonex announced the approval of an Investigational New Drug (IND) application by the Ministry of Food and Drug Safety (MFDS) for revolutionary mRNA vaccine candidate, LEM-mR203, which incorporates their pioneering nano-drug delivery technology, DegradaBALL®.

The scope of this clinical trial encompasses the evaluation of safety and immunogenicity in healthy adults with a specific focus on addressing the ongoing Covid-19 pandemic. Distinguished by its unique attribute, LEM-mR203 is the first mRNA vaccine candidate to integrate the proprietary drug delivery platform technology, DegradaBALL-mRNA system. 

The current lipid nanoparticle (LNP) technology used in existing mRNA vaccines has problems related to allergic reactions or heart issues like myocarditis. The newly developed DegradaBALL drug delivery technology holds promise in mitigating these concerns, suggesting advancement for mRNA vaccines and therapeutics.

The mRNA vaccines offer an accelerated response due to their rapid development cycle compared to antigen protein vaccines. Nevertheless, the efficacy of mRNA delivery within the body hinges on proficient drug delivery technology.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024